Yetty Hambarsari

Yetty Hambarsari

Auto-generated profile, based on publicly available information

Yetty Hambarsari

Department of Neurology, Faculty of Medicine Universitas Sebelas Maret Surakarta Indonesia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025
Verified
Journal Article
Open access
YHYetty Hambarsari
Yetty Hambarsari
SSSuroto Suroto
Suroto Suroto
DMDiah Kurnia Mirawati
Diah Kurnia Mirawati
SSSoetrisno Soetrisno
Soetrisno Soetrisno
PDParamasari Dirgahayu
Paramasari Dirgahayu
VWVitri Widyaningsih
Vitri Widyaningsih
Context: Alzheimer’s Disease (AD) is a neurodegenerative disorder with limited treatment options, primarily addressing symptoms without targeting underlying mechanisms. Emerging therapies involving secretomes, exosomes, and extracellular vesicles (EVs) show promise in modulating AD pathology, including amyloid-beta accumulation, tau aggregation, and neuroinflammation. Aims: To conduct a bibliometric analysis of global research on secretomes, exosomes, and EVs in AD to identify trends, key contributors, and future research directions. Methods: A bibliometric analysis was conducted using the Scopus database. A total of 988 studies were identified based on English-language and final publication-stage studies, reviews, and conference papers. The data were analyzed using Scopus tools, the bibliometrics R package (Biblioshiny), and VOSviewer to evaluate publication trends, key contributors, and keyword co-occurrence networks. Results: Research on secretomes, exosomes, and EVs in AD has grown steadily from 2003 to 2025, with a significant increase in publications since 2010. The studies span 397 sources, with an annual growth rate of 6.5% and a high average citation rate per article (65.55). Key topics included fundamental mechanisms (e.g., neuroinflammation, amyloid-beta, tauopathy), biomarker development, and therapeutic approaches. Emerging areas requiring further exploration include clinical applications (e.g., delivery systems), novel biomarkers (e.g., gut–brain axis indicators), and advanced analytical methods (e.g., machine learning, bioinformatics). Conclusions: This study reveals an expanding global interest in the role of secretomes, exosomes, and EVs in AD. It identifies significant trends and research gaps, emphasizing the need for translational efforts that bridge experimental insights and clinical applications. Future efforts should focus on translating promising findings into clinical applications while addressing underexplored topics and fostering international collaboration.

1 January 2024 in Journal of Applied Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
YHYetty Hambarsari
Yetty Hambarsari
SSSuroto Suroto
Suroto Suroto
DMDiah Kurnia Mirawati
Diah Kurnia Mirawati
SSSoetrisno Soetrisno
Soetrisno Soetrisno
BWBrian Wasita
Brian Wasita
Stefanus Erdana PutraStefanus Erdana Putra
Stefanus Erdana Putra
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a rapidly increasing prevalence. Current therapeutic options primarily manage symptoms, not modifying the disease. Secretome-based therapies have emerged as a promising avenue for AD treatment in targeting multiple pathways and promoting neuroprotection and regeneration. This systematic review evaluated the preclinical and clinical evidence for secretome-based therapies in AD. A systematic search was conducted across Scopus, PubMed, ScienceDirect, and Cochrane Library. The Systematic Review Protocol for Animal Intervention Studies risk of bias (RoB) tool was used for preclinical studies and Cochrane RoB 2.0 for clinical studies. We performed a qualitative analysis of the study results. Included 21 in vivo studies and 2 clinical trials revealed promising outcomes of treatments involving secretomes, exosomes, and extracellular vesicles from different cell sources. The therapies could reduce amyloid plaque load, reactive gliosis, and enhance neuronal density. These findings suggested the treatments reveal mechanisms of action in neuroprotection, neuroregeneration, and inflammation modulation, which are critical in AD pathology. Ongoing trials also supported the safety and efficacy of the treatment strategies. However, translational medical study faces several challenges regarding large-scale production, optimization of protocols, and understanding biomarkers. The heterogeneity in secretome-based therapy administration has complicated the comparison of study outcomes and the translation of preclinical findings into clinical settings. A deeper understanding of the secretome’s mechanisms of action, optimal dosing, and delivery methods are needed to maximize therapeutic outcomes. Despite secretome-based therapies holding significant promise for AD treatment, addressing the identified gaps and limitations is crucial for advancing these therapies from preclinical research to clinical practice.

5 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
YHYetty Hambarsari
Yetty Hambarsari
SSSuroto Suroto
Suroto Suroto
DMDiah Kurnia Mirawati
Diah Kurnia Mirawati
SSSoetrisno Soetrisno
Soetrisno Soetrisno
BWBrian Wasita
Brian Wasita
SPStefanus Erdana Putra
Stefanus Erdana Putra
Background: Alzheimer's Disease (AD) is a progressive neurodegenerative disorder with a rapidly increasing prevalence. Current therapeutic options primarily manage symptoms, not modifying the disease. Secretome-based therapies have emerged as a promising avenue for AD treatment in targeting multiple pathways and promoting neuroprotection and regeneration. This systematic review evaluated the preclinical and clinical evidences for secretome-based therapies in AD.Methods: A systematic search was conducted across Scopus, PubMed, ScienceDirect, and Cochrane Library. The SYRCLE risk of bias (RoB) tool was used for preclinical studies and Cochrane RoB 2.0 for clinical studies. We performed qualitative analysis of study results.Results: Included 21 in vivo studies and 2 clinical trials revealed promising outcomes of treatments involving secretomes, exosomes, and extracellular vesicles from different cell sources. The therapies could reduce amyloid plaque load, reactive gliosis, and enhance neuronal density. These findings suggested the treatments reveal mechanism of action in neuroprotection, neuroregeneration, and inflammation modulation, which are critical in AD pathology. Ongoing trials also supported the safety and efficacy of the treatment strategies. However, translational medical study faces several challenges regarding large-scale production, optimization of protocols, and understanding biomarkers. The heterogeneity in secretome-based therapies administration have complicated the comparison of study outcomes and the translation of preclinical findings into clinical settings. Deeper understanding of the secretome's mechanisms of action, optimal dosing, and delivery methods are needed to maximize therapeutic outcomes.Conclusion: Despite secretome-based therapies hold significant promise for AD treatment, addressing the identified gaps and limitations is crucial for advancing these therapies from preclinical research to clinical practice.

6 September 2021 in Biomedika
Verified
Journal Article
Open access
PDF file
YHYetty Hambarsari
Yetty Hambarsari
RDRivan Danuaji
Rivan Danuaji
BHBaarid Luqman Hamidi
Baarid Luqman Hamidi
PUPriyanka Ganesa Utami
Priyanka Ganesa Utami
BSBefrie Mahaztra Sudarman
Befrie Mahaztra Sudarman
PENGARUH JENIS KELAMIN TERHADAP BESARAN MOTOR TRESHOLD (MT) MENGGUNAKAN TRANSCRANIAL MAGNETIC STIMULATION (TMS)

7 March 2025 in Epilepsia Open
Verified
Journal Article
Open access
DMDiah Kurnia Mirawati
Diah Kurnia Mirawati
MIMuhana Fawwazy Ilyas
Muhana Fawwazy Ilyas
MHMuhammad Hafizhan
Muhammad Hafizhan
Stefanus Erdana PutraStefanus Erdana Putra
Stefanus Erdana Putra
SSSuroto Suroto
Suroto Suroto
FSFaris Khairuddin Syah
Faris Khairuddin Syah
Objectives: Genetic‐associated epilepsy in the Indonesian population is rarely discussed, and no study was specifically studied about photosensitive epilepsy. The fundamental goal of this research endeavor was to evaluate whether the single nucleotide polymorphism (SNP) of the Bromodomain‐Containing Protein 2 (BRD2) gene gives vulnerability to photosensitive epilepsy among Indonesian descent.Methods: This observational case–control study includes patients of Indonesian descent with Javanese ancestry. Clinical and neurophysiological data, along with electroencephalographic (EEG) recordings, were used to diagnose epilepsy and photosensitive epilepsy. Blood samples were collected and analyzed for BRD2 gene SNPs (rs206781, rs188245, and rs15912) using polymerase chain reaction (PCR), electrophoresis, and the Sanger sequencing method.Results: This study included 27 participants, consisting of 17 patients in the epilepsy group (nine patients with photosensitive epilepsy and eight patients without photosensitive epilepsy) and 10 patients in the non‐epilepsy group. Significant statistical differences were found in genotype (rs206781, p = 0.008 and rs188245, p = 0.004) and allele frequencies (rs206781, p < 0.001 and rs188245, p < 0.001) of the BRD2 gene in Indonesian descent with Javanese race patients diagnosed with photosensitive epilepsy and in those without this condition.Significance: Our study corroborates the observation that genetic diversity within the BRD2 locus (rs206781 and rs188245) is associated with PE in Indonesian descendants of the Javanese race. To acquire a complete knowledge of the development of photosensitive epilepsy, further polymorphism studies at other SNP locations or genes are necessary.Plain Language Summary: This study investigated whether genetic differences in the BRD2 gene were linked to photosensitive epilepsy (a type of epilepsy triggered by visual stimuli like flashing lights) in individuals of Indonesian Javanese descent. We analyzed deoxyribonucleic acid (DNA) samples from patients with epilepsy, including those with photosensitive epilepsy, and found that certain variations in the BRD2 gene were significantly more common in people with photosensitive epilepsy. These findings imply that genetic factors, specifically variations in the BRD2 gene, could elevate the risk of individuals in this population experiencing photosensitive epilepsy.

23 January 2024 in Smart Medical Journal
Verified
Journal Article
Open access
PDF file
SSSubandi Subandi
Subandi Subandi
SSSuroto Suroto
Suroto Suroto
DMDiah Kurnia Mirawati
Diah Kurnia Mirawati
RDRivan Danuaji
Rivan Danuaji
PBPepi Budianto
Pepi Budianto
Stefanus Erdana PutraStefanus Erdana Putra
Stefanus Erdana Putra
Introduction: Vertebrobasilar artery stenosis can be extracranial or intracranial, and accounts for up to 20% of posterior circulation ischemic strokes. The gold standard for diagnosing is Digital Subtraction Angiography (DSA), an invasive diagnostic method by injecting a contrast agent into the blood vessels leading to the brain through a catheter. This study aims to determine the profile of patients with intracranial and extracranial vertebrobasilar artery stenosis who underwent DSA procedures.Methods: This descriptive research was conducted in RSUD Dr. Moewardi in patients who underwent DSA procedures for the period January 2020 to March 2022 and found vertebrobasilar artery stenosis. The study samples were grouped based on the location of the stenosis; intracranial and extracranial. The data collected included age, gender, symptoms, risk factors, degree of stenosis, and angiographic findings.Results: Of 42 subjects, 33 (78.6%) patients were male. There are 23 (54.8%) patients with intracranial vertebrobasilar stenosis and 19 (45.2%) patients in extracranial. The main symptoms included hemiparesis, vertigo, hemiesthesia, loss of consiciousness, aphasia, dysartria, and dysphagia. The risk factors were 36 (85.7%) patients with hypertension, 18 (42.9%) patients with diabetes mellitus, 18 (42.9%) patients with a history of smoking, and 13 (31%) patients with hyperlipidemia. A total of 8 patients underwent stenting/angioplasty.Conclusion: The prevalence of vertebrobasilar artery stenosis increases with age, most commonly occurring at the age of 50-59 years..The most common risk factor for vertebrobasilar artery stenosis is hypertension. Management recommendations include a combination of antiplatelet and endovascular therapy.